BackInhibikase Therapeutics Overview

Inhibikase Therapeutics Long Term Debt

Inhibikase Therapeutics's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Inhibikase Therapeutics Long Term Debt History

Loading

Inhibikase Therapeutics vs. peers: Long Term Debt Comparison

Loading

Inhibikase Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inhibikase Therapeutics (IKT) FAQ

As of the most recent data (June 2026), IKT shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IKT's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Inhibikase Therapeutics is outperforming or lagging.

Tracking IKT's long-term debt over time shows whether Inhibikase Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Inhibikase Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Inhibikase Therapeutics's long-term debt is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.